Drug-induced liver hypersensitivity disease (Q43584): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
Doença de hipersensibilidade hepática induzida por droga é uma condição, relativamente, rara, mas que pode ter consequências sérias para o indivíduo, a saúde pública, as agências regulatórias e a indústria farmacêutica. Caracteriza-se pela elevação no soro de alanina aminotransferase (ALT), bilirrubina conjugada, ou bilirrubina combinada, ALT e fosfatase alcalina (FA) por > 2 vezes o limite superior do normal; e as drogas mais frequentemente relacionadas são halotano, ácido tienílico, di-hidralazina, diclofenaco e carbamazepina. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/674464254 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:4A85.00 | |||||||||||||||
| Property / CURIE: CID11:4A85.00 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-4A85.00 | |||||||||||||||
| Property / Canary Token: dki-india-4A85.00 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Linked ICD 10 | |||||||||||||||
| Property / Linked ICD 10: K71 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 10:39, 13 August 2026
Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 4A85.00 |
||
| English | Drug-induced liver hypersensitivity disease |
Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine. |
Statements
CID11:4A85.00
0 references
dki-india-4A85.00
0 references
Concluído
0 references
13 August 2026
0 references
